A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/5513 (2006.01) A61K 31/5517 (2006.01) A61K 31/553 (2006.01) A61K 31/554 (2006.01) A61P 1/04 (2006.01) A61P 11/00 (2006.01) A61P 19/02 (2006.01) A61P 27/02 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2573674
x The present invention relates generally to the cytoprotective activity of mixed muscarinic inhibition/PARP modulation and in particular to the use of dual inhibitors of M1 muscarinic receptor and poly(ADP-ribose) polymerase (PARP) as epithelioprotective medicaments, particularly as medicaments for the prevention and/or treatment of at least one of the common lung diseases associated with a significant inflammatory component such as severe sepsis, acute lung injury, acute respiratory distress syndrome, cystic fibrosis, asthma, allergic rhinitis, chronic obstructive pulmonary disease, pulmonary fibrosis, systemic sclerosis, pneumoconiosis or lung cancer. Particularly preferred compounds are condensed diazepinones, e.g. condensed benzodiazepinones such as pirenzepine or compounds which are metabolized to condensed benzodiazepinones such as olanzapine.
De façon générale, la présente invention concerne l'activité cytoprotectrice de l'inhibition muscarinique/modulation PARP mixtes et singulièrement l'utilisation d'inhibiteurs du récepteur muscarinique M1 et de la poly(ADP-ribose)polymérase (PARP) comme médicaments épithélioprotecteurs, en particulier pour la prévention et/ou le traitement d'au moins l'une des affections pulmonaires communes associéesà une composante inflammatoire majeure telles que sepsis grave, lésion pulmonaire aiguë, syndrome respiratoire aigu sévère, fibrose cystique, asthme, rhinite allergique, maladie pulmonaire obstructive chronique, fibrose pulmonaire, sclérose systémique, pneumoconiose ou cancer du poumon Sont de loin préférables des composés de diazépinones condensés, c'est-à-dire des benzodiazépinones condensés tels que la pirenzépine ou des composés qui sont métabolisés en benzodiazépinones condensés tels que l'olanzapine.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
Proteosys Ag
LandOfFree
Muscarinic antagonists with parp and sir modulating activity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Muscarinic antagonists with parp and sir modulating activity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Muscarinic antagonists with parp and sir modulating activity... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2080775